Phase I dose-ranging trial of OMS 824 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2014
At a glance
- Drugs OMS 824 (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Adverse reactions
- 01 Apr 2014 Results will be presented at the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) according to an Omeros Corporation media release.
- 26 Mar 2013 Status changed from recruiting to completed.
- 26 Mar 2013 Results from multiple dose part of study published in an Omeros media release.